Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer.

Abstract

In this phase II study, 23 patients with metastatic breast cancer were treated with a combination of Caelyx (40 mg/m2 on day 1) and vinorelbine (20 mg/m2 on days 1 and 8) every 4 weeks. According to the statistical design, enrollment was closed after the first stage due to the low response rate observed (four partial remissions, 12 stabilizations). Toxicity was acceptable, however, grade 3-4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer.

• Authors: Lorenza Rimassa, Carlo Carnaghi, Isabella Garassino, Piermario Salvini, Valeria Ginanni, Giuseppe Gullo, Emanuela Morenghi, Armando Santoro
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 77 Issue 2 Pg. 185-8 (Jan 2003) ISSN: 0167-6806 [Print] Netherlands
• PMID: 12602917 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Liposomes
• Vinblastine
• Doxorubicin
• Vinorelbine

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy)
• Doxorubicin (administration & dosage)
• Female
• Humans
• Liposomes
• Middle Aged
• Neoplasm Metastasis
• Remission Induction
• Treatment Outcome
• Vinblastine (administration & dosage, analogs & derivatives)
• Vinorelbine